Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient

Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient

Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary,...

Full description

Bibliographic Details
Main Authors: George Samonis, Aikaterini Bousmpoukea, Aristea Molfeta, Antonios D. Kalkinis, Kalliopi Petraki, Christos Koutserimpas, Dimitrios Bafaloukos
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Diagnostics
Subjects:
nivolumab
gastritis
melanoma
corticosteroids
Online Access:https://www.mdpi.com/2075-4418/12/11/2864

Similar Items

Similar Items